Research programme: reproductive health therapeutics - Pantarhei Biosciences

Drug Profile

Research programme: reproductive health therapeutics - Pantarhei Biosciences

Alternative Names: BLACE; OTE F; Oxytocin/estrogen - Pantarhei Biosciences; Renin angiotensin system suppressors - Pantarhei Biosciences; Testetrol - Pantarhei Biosciences

Latest Information Update: 20 Nov 2015

Price : $50

At a glance

  • Originator Pantarhei Bioscience
  • Class Hormonal replacements; Hormones
  • Mechanism of Action ACE inhibitors; Angiogenesis inhibitors; Angiotensin receptor antagonists; Estrogen receptor agonists; Oxytocin receptor agonists; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Female testosterone deficiency; Hypogonadism
  • Research Male infertility; Menopausal syndrome

Most Recent Events

  • 21 Oct 2015 Early research in Menopausal syndrome in Netherlands (unspecified route)
  • 21 Oct 2015 Preclinical trials in Hypogonadism in Netherlands (PO)
  • 21 Oct 2015 Preclinical trials in Female testosterone deficiency in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top